- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00836823
Evaluation of Symptom-specific Goal Achievement
October 30, 2023 updated by: KYU-SUNG LEE, Samsung Medical Center
The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility
Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) consists of a constellation of symptoms (including voiding, storage, and post-micturition).
The impact of the LUTS on patients' health-related quality of life is substantial and multifaceted.
Thus, the therapies aimed at treating BPH are concerned primarily with improving patients' symptoms, thereby improving quality of life.
When multiple symptoms are present, the level of bother associated with individual symptoms varies and patients prioritize their treatment goals for symptom relief.
A measure that addresses patients' most bothersome symptoms (MBS) and evaluation of symptom-specific goal achievements may lead to improved outcomes and patient satisfaction to the treatment.
The objectives of this study were (1) to assess patient-reported MBS and symptom-specific goal achievements (PGA) with medical treatment in BPH patients, and (2) to identify factors that influence or have relation to the PGA.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
130
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Asan Medical Center, Ulsan College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- males ≥50 years with LUTS secondary to BPH
- Moderate to severe LUTS : IPSS ≥ 8
- An enlarged prostate : TRUS ≥25 mL
- Decreased peak flow rate : Qmax ≤15mL/s (volume voided ≥ 120 mL)
- Having signed the informed consent to participate in the study.
Exclusion Criteria:
- Post voided residual urine ≥ 200mL
- Patients performing catheterization
- Urinary tract infection patients
- Patients taking 5 alpha reductase inhibitor
- Known hypersensitivity to alfuzosin
- History of postural hypotension or syncope
- Hypertension patients treated with other alpha1-blockers
- Patients newly taking anticholinergic medication within 1 month
- Hepatic insufficiency (AST/ALT ≥ 2 times of normal range)
- Renal insufficiency (s-Cr ≥ 2mg/dL)
- Unstable angina pectoris
- Uninvestigated hematuria
- Serum PSA ≥ 4 ng/mL (biopsy proven no cancer patients can be included)
- Interstitial cystitis patients
- Severe concomitant condition threatening life.
- Patient who is unable to make voiding diary
- Bladder or prostate cancer patients
- Patients receiving prostate or bladder surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alpha blocker
Alfuzosin 10mg
|
Alfuzosin 10mg once daily for 12 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient-reported goal achievements for the most bothersome symptoms
Time Frame: 12 months of treatment
|
12 months of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient-reported goal achievement for the most bothersome symptom using Likert scale
Time Frame: 3, 6, and 12 months of treatment
|
3, 6, and 12 months of treatment
|
Changes in: IPSS, ICS-male questionnaire, maximal flow rate, post-voided residual urine, voiding chart parameters
Time Frame: 3, 6, and 12 months of treatment
|
3, 6, and 12 months of treatment
|
Global impression of improvement
Time Frame: 3, 6, and 12 months of treatment
|
3, 6, and 12 months of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kyu-Sung Lee, Ph.D, Samsung Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2005
Primary Completion (Actual)
August 1, 2008
Study Completion (Actual)
August 1, 2008
Study Registration Dates
First Submitted
February 2, 2009
First Submitted That Met QC Criteria
February 3, 2009
First Posted (Estimated)
February 4, 2009
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 30, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Urological Manifestations
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Lower Urinary Tract Symptoms
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Alfuzosin
Other Study ID Numbers
- 2005-10-044
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lower Urinary Tract Symptoms
-
The Royal College of Surgeons of EnglandUniversity College, LondonCompletedUncomplicated Lower Urinary Tract Symptoms
-
National Taiwan University HospitalUnknownDisorder of the Lower Urinary TractTaiwan
-
ProVerum MedicalNot yet recruitingBPH With Symptomatic Lower Urinary Tract Symptoms
-
The University of Texas Medical Branch, GalvestonCompletedLower Urinary Tract Symptoms | Lower Gastrointestinal Tract Symptoms
-
Baylor Research InstituteForte MedicalCompletedLower Urinary Tract Symptoms | Lower Urinary Tract InfectionUnited States
-
Far Eastern Memorial HospitalCompletedPsychiatric Aspects in Women With Lower Urinary Tract SymptomsTaiwan
-
Jagiellonian UniversityPiotr ChlostaCompletedTo Evaluate Lower Urinary Tract Symptoms (LUTS) in PolandPoland
-
Boston Scientific CorporationTerminatedBPH | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States, Australia
-
Benaroya Research InstituteVirginia Mason Hospital/Medical CenterUnknownPain | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States
-
San Carlo di Nancy HospitalLampugnani Farmaceutici S.p.A. (Nerviano, Milan, Italy)CompletedBPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsItaly
Clinical Trials on Alfuzosin
-
Unity Health TorontoSanofiWithdrawn
-
SanofiCompleted
-
International Bio serviceNot yet recruiting
-
SanofiCompleted
-
Singapore General HospitalSanofiWithdrawn
-
Hospital Authority, Hong KongTerminatedProstatic Hyperplasia | Acute Disease | Urinary RetentionChina
-
Torrent Pharmaceuticals LimitedCompleted
-
University Hospitals Cleveland Medical CenterSanofiCompletedErectile Dysfunction | BPHUnited States
-
SanofiCompletedProstatic Hyperplasia | Urinary Retention | Benign Prostatic HypertrophyUnited States, Canada, Poland, Romania, Australia, Netherlands, Portugal, Spain, Sweden, Bulgaria, Denmark, Finland, Hungary, Norway, South Africa, Greece, Israel